Bucolome
Appearance
Clinical data | |
---|---|
Other names | Bucolome, Paramidine |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.011.515 |
Chemical and physical data | |
Formula | C14H22N2O3 |
Molar mass | 266.341 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Bucolome (Paramidine) is a barbiturate derivative. Unlike most barbiturates it does not have any significant sedative or hypnotic effects, but instead acts as an analgesic and antiinflammatory. It also acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.[1][2][3]
References
- ^ Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.
- ^ Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. (April 2005). "Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions". International Journal of Pharmaceutics. 293 (1–2): 43–9. doi:10.1016/j.ijpharm.2004.12.009. PMID 15778043.
- ^ Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008). "The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115–9. doi:10.2133/dmpk.23.115. PMID 18445991.